Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 13/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 1.00 |
| ▸ | MAPT | P10636 | 5/20 | 1.00 |
| ▸ | TP53 | P04637 | 4/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 1.00 |
| ▸ | MIF | P14174 | 1/20 | 0.79 |
| ▸ | USP2 | O75604 | 10/20 | 0.77 |
| ▸ | MEN1 | O00255 | 1/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.77 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.76 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.71 |
| ▸ | SLCO1B3 | Q9NPD5 | 3/20 | 0.70 |
| ▸ | SLCO1B1 | Q9Y6L6 | 3/20 | 0.70 |
| ▸ | APEX1 | P27695 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gedunin SCHEMBL10019479 | 1.00 | CYP3A4 (1.00) | CYP3A4SMN1; SMN2MAPTTP53LMNA | |
| Gedunin SCHEMBL16731398 | 1.00 | CYP3A4 (1.00) | CYP3A4SMN1; SMN2MAPTTP53LMNA | |
| Gedunin SCHEMBL17603575 | 1.00 | CYP3A4 (1.00) | CYP3A4SMN1; SMN2MAPTTP53LMNA | |
| Gedunin SCHEMBL12664640 | 1.00 | CYP3A4 (1.00) | CYP3A4SMN1; SMN2MAPTTP53LMNA | |
| Gedunin SCHEMBL14197009 | 1.00 | CYP3A4 (1.00) | CYP3A4SMN1; SMN2MAPTTP53LMNA | |
| Gedunin SCHEMBL23134885 | 1.00 | CYP3A4 (1.00) | CYP3A4SMN1; SMN2MAPTTP53LMNA | |
| Gedunin SCHEMBL12998444 | 1.00 | CYP3A4 (1.00) | CYP3A4SMN1; SMN2MAPTTP53LMNA | |
| SCHEMBL17612264 | 0.92 | CYP3A4 (0.85) | CYP3A4SMN1; SMN2MAPTTP53LMNA | |
| SCHEMBL15604116 | 0.92 | CYP3A4 (0.85) | CYP3A4SMN1; SMN2MAPTTP53LMNA | |
| SCHEMBL16727974 | 0.92 | CYP3A4 (0.85) | CYP3A4SMN1; SMN2MAPTTP53LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 543 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260076366-A1 | SYNERGISTIC PESTICIDAL COMPOSITIONS AND METHODS FOR DELIVERY OF ACTIVE INGREDIENTS | 0903608 B C LTD (CA) | 2026-03-19 | — | — | US | claimed |
| EP-4642465-A1 | A CANCER ASSOCIATED FIBROBLAST (CAF) INHIBITOR FOR USE WITH AN ALTERNATING ELECTRIC FIELD IN A METHOD OF TREATING DISEASES SUCH AS CANCER | Novocure GmbH (CH) | 2025-11-05 | — | — | EP | claimed |
| EP-4580612-A1 | USE OF NRF2 ACTIVATORS FOR THE TREATMENT OF CEREBRAL SMALL VESSEL DISEASE | Institut National de la Santé et de la Recherche Médicale (FR) | 2025-07-09 | — | — | EP | claimed |
| CN-119235819-A | Multifunctional bionic nano-drug and preparation method and application thereof | 燕山大学 | 2025-01-03 | — | — | CN | claimed |
| CN-118311257-A | Target marker for diagnosis or treatment of cervical neuroendocrine cancer and application thereof | 安徽师范大学 | 2024-07-09 | — | — | CN | claimed |
| WO-2024141952-A1 | A CANCER ASSOCIATED FIBROBLAST (CAF) INHIBITOR FOR USE WITH AN ALTERNATING ELECTRIC FIELD IN A METHOD OF TREATING DISEASES SUCH AS CANCER | NOVOCURE GMBH (CH) | 2024-07-04 | — | — | WO | claimed |
| US-20240216403-A1 | METHODS AND COMPOSITIONS FOR INHIBITING FIBROBLAST ACTIVATION | BIOPHARMA CREDIT PLC (GB) | 2024-07-04 | — | — | US | claimed |
| WO-2024047248-A1 | USE OF NRF2 ACTIVATORS FOR THE TREATMENT OF CEREBRAL SMALL VESSEL DISEASE | Institut National de la Santé et de la Recherche Médicale (FR) | 2024-03-07 | — | — | WO | claimed |
| US-20240041038-A1 | INSECTICIDAL COMBINATIONS | Vestaron Corporation (US) | 2024-02-08 | — | — | US | claimed |
| US-20230392214-A1 | Systems and Methods for Assessing Mutational Burden of Neoplasms And Associated Treatments Thereof | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2023-12-07 | — | — | US | claimed |
| US-20100298280-A1 | Compounds for the Modulation of Huntingtin Aggregation, Methods and Means for Identifying Such Compounds | KIOSCHIS-SCHNEIDER PETRA | 2010-11-25 | — | — | US | claimed |
| WO-2010053573-A2 | SCREEN FOR INHIBITORS OF FILOVIRUS AND USES THEREFOR | KAWAOKA YOSHIHIRO (US) | 2010-05-14 | — | — | WO | claimed |
| EP-2164865-A2 | COMPOUNDS FOR THE MODULATION OF HUNTINGTIN AGGREGATION, METHODS AND MEANS FOR IDENTIFYING SUCH COMPOUNDS | Hochschule Mannheim (DE) | 2010-03-24 | — | — | EP | claimed |
| CN-101330921-A | An extract from xylocarpus useful for the treatment of diabetes and dyslipidemia | COUNCIL SCIENT IND RES (IN) | 2008-12-24 | — | — | CN | claimed |
| WO-2008151833-A2 | COMPOUNDS FOR THE MODULATION OF HUNTINGTIN AGGREGATION, METHODS AND MEANS FOR IDENTIFYING SUCH COMPOUNDS | HOCHSCHULE MANNHEIM (DE) | 2008-12-18 | — | — | WO | claimed |
| EP-1940435-A2 | AN EXTRACT FROM XYLOCARPUS USEFUL FOR THE TREATMENT OF DIABETES AND DYSLIPIDEMIA | Council of Scientific and Industrial Research (IN) | 2008-07-09 | — | — | EP | claimed |
| WO-2007117466-A2 | CELASTROL, GEDUNIN, AND DERIVATIVES THEREOF AS HSP90 INHIBITORS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2007-10-18 | — | — | WO | claimed |
| US-20070178179-A1 | Pharmaceutical composition for treatment of diabetes and dyslipidemia | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2007-08-02 | — | — | US | claimed |
| WO-2007031830-A2 | AN EXTRACT FROM XYLOCARPUS USEFUL FOR THE TREATMENT OF DIABETES AND DYSLIPIDEMIA | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2007-03-22 | — | — | WO | claimed |
| CN-1359623-A | Nim extract mixture as agricultural chemical and its preparing process | YINGDELI BIO TECHNOLOGY DEV CO (CN) | 2002-07-24 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298280-A1 | Compounds for the Modulation of Huntingtin Aggregation, Methods and Means for Identifying Such Compounds | HTT, PSMG3, HYPK | CYP3A4 4834/4885SMN1; SMN2 910/4885MAPT 21/4885 |
| US-20260076366-A1 | SYNERGISTIC PESTICIDAL COMPOSITIONS AND METHODS FOR DELIVERY OF ACTIVE INGREDIENTS | TACR3, GSTO1, TIAL1 | CYP3A4 1293/4885SMN1; SMN2 1799/4885MAPT 2320/4885 |
| US-20070178179-A1 | Pharmaceutical composition for treatment of diabetes and dyslipidemia | LPL, LIPC, PNLIP | CYP3A4 1491/4885SMN1; SMN2 4253/4885MAPT 3045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.